Axsome Therapeutics Inc (NASDAQ:AXSM) price on Friday, February 07, fall -3.42% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $105.76.
A look at the stock’s price movement, the close in the last trading session was $109.50, moving within a range at $105.51 and $109.99. The beta value (5-Year monthly) was 1.252. Turning to its 52-week performance, $114.06 and $64.11 were the 52-week high and 52-week low respectively. Overall, AXSM moved 26.24% over the past month.
Axsome Therapeutics Inc’s market cap currently stands at around $5.13 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 118.42M for the company’s revenue for the quarter, with a low and high estimate of 113.9M and 123.21M respectively. The average forecast suggests up to a 65.56% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 385.53M, representing a 42.47% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that AXSM is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
15 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 13 recommend AXSM as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
AXSM’s current price about 5.03% and 10.57% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 57.33, while 7-day volatility ratio is 3.99% and 4.93% in the 30-day chart. Further, Axsome Therapeutics Inc (AXSM) has a beta value of 1.03, and an average true range (ATR) of 4.54. Analysts have given the company’s stock an average 52-week price target of $137, forecast between a low of $132 and high of $190. Looking at the price targets, the low is -24.81% off current price level while to achieve the yearly target high, price needs to move -79.65%. Nonetheless, investors will most likely welcome a -29.54% jump to $137 which is the analysts’ median price.
If we refocus on Axsome Therapeutics Inc (NASDAQ:AXSM), historical trading data shows that trading volumes averaged 0.88 over the past 10 days and 789.91K over the past 3 months. The company’s latest data on shares outstanding shows there are 48.44 million shares.
The 18.28% of Axsome Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 79.80% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 5.75 million on 2025-01-15, giving us a short ratio of 6.08. The data shows that as of 2025-01-15 short interest in Axsome Therapeutics Inc (AXSM) stood at 1422.0000999999997 of shares outstanding, with shares short falling to 6.52 million registered in 2024-12-13. Current price change has pushed the stock 25.00% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AXSM stock continues to rise going into the next quarter.
